Mylan's Robert Coury returns to exec chairman role amid pandemic, delayed merger

Citing an "unprecedented" operating environment due to the COVID-19 pandemic, Mylan said Robert Coury will return to his role as executive chairman.

Mr. Coury served as Mylan's executive chairman between 2012 and 2016 and also served as the company's CEO for 10 years.

Mylan said they were appointing Mr. Coury to the role of executive chairman to help the generic drugmaker through the pandemic and a delayed merger with Upjohn, Pfizer's generic drug business.